Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-4217903 in Patients With Advanced Cancer.
Latest Information Update: 30 Jun 2012
At a glance
- Drugs PF 4217903 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 22 Jun 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.